Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Payables (2021 - 2025)

Bioregenx has reported Payables over the past 5 years, most recently at $1.6 million for Q4 2025.

  • For Q4 2025, Payables rose 23.53% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, up 23.53%, while the annual FY2025 figure was $1.6 million, 23.53% up from the prior year.
  • Payables for Q4 2025 was $1.6 million at Bioregenx, up from $1.5 million in the prior quarter.
  • Over five years, Payables peaked at $1.6 million in Q4 2025 and troughed at $11996.0 in Q4 2021.
  • A 5-year average of $828603.1 and a median of $1.1 million in 2024 define the central range for Payables.
  • Biggest five-year swings in Payables: skyrocketed 3394.4% in 2024 and later dropped 21.92% in 2025.
  • Year by year, Payables stood at $11996.0 in 2021, then soared by 405.93% to $60691.0 in 2022, then surged by 917.24% to $617376.0 in 2023, then surged by 112.31% to $1.3 million in 2024, then increased by 23.53% to $1.6 million in 2025.
  • Business Quant data shows Payables for BRGX at $1.6 million in Q4 2025, $1.5 million in Q3 2025, and $1.5 million in Q2 2025.